Erratum: Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression (Journal of Clinical Investigation (2018) 128:2 (805-815) DOI: 10.1172/JCI96113);Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Journal of Clinical Investigation

Volumn 128, Issue 2, 2018, Pages 805-815

  Lin, Heng ^a   Wei, Shuang ^a   Hurt, Elaine M ^b   Green, Michael D ^a   Zhao, Lili ^a   Vatan, Linda ^a   Szeliga, Wojciech ^a   Herbst, Ronald ^b   Harms, Paul W ^a   Fecher, Leslie A ^a   Vats, Pankaj ^a   Chinnaiyan, Arul M ^a,c   Lao, Christopher D ^a   Lawrence, Theodore S ^a,c   Wicha, Max ^a,c   Hamanishi, Junzo ^d   Mandai, Masaki ^d   Kryczek, Ilona ^a   Zou, Weiping ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MEDIMMUNE   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR; CD274 PROTEIN, HUMAN; CD274 PROTEIN, MOUSE; CYTOKINE; HOMEODOMAIN PROTEIN; RAG-1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; B16-F10 CELL LINE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; ENDOMETRIOID CARCINOMA; HUMAN; HUMAN CELL; ID8 CELL LINE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; LYMPH NODE; MACROPHAGE; MALE; MC-38 CELL LINE; MELANOMA; METASTATIC MELANOMA; MOUSE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DENDRITE; ENDOMETRIUM TUMOR; EXPERIMENTAL MELANOMA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; SCID MOUSE; SKIN TUMOR; TIME FACTOR; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; B7-H1 ANTIGEN; CELL LINE, TUMOR; CYTOKINES; DENDRITES; DENDRITIC CELLS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; LYMPH NODES; MACROPHAGES; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, SCID; OVARIAN NEOPLASMS; SKIN NEOPLASMS; TIME FACTORS; TUMOR MICROENVIRONMENT;

EID: 85041487825     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI120803     Document Type: Erratum

References (42)

1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
2. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. SciTranslMed. 2016;8(328):328rv4.
3. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature. 2012;482(7385):405–409.
4. Matsushita H, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400–404.
5. Tran E, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–645.
6. Linnemann C, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2015;21(1):81–85.
7. Robbins PF, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–752.
8. Carreno BM, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803–808.
9. Llosa NJ, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51.
10. Hamanishi J, et al. Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022.
11. Homet Moreno B, et al. Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. CancerImmunolRes. 2016;4(10):845–857.
12. Peng D, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249–253.
13. Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
14. Powles T, et al. MPDL3280A (anti–PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–562.
15. Herbst RS, et al. Predictive correlates of response to the anti–PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
16. Kleffel S, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162(6):1242–1256.
17. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122.
18. Xiao Y, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014;211(5):943–959.
19. Brahmer JR, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
20. Topalian SL, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
21. Garon EB, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
22. Reck M, et al. Pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
23. Taube JM, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
24. Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319.
25. Brahmer J, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
26. Curiel TJ, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562–567.
27. Perrot I, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. JImmunol. 2007;178(5):2763–2769.
28. Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res. 2009;69(20):8067–8075.
29. Kuang DM, et al. Activated monocytes in peritu-moral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. JExpMed. 2009;206(6):1327–1337.
30. Juneja VR, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895–904.
31. Lau J, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:14572.
32. Larkin J, et al. Combined nivolumab and ipilim-umab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
33. Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.
34. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc NatlAcadSciUSA. 2002;99(19):12293–12297.
35. Shin DS, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7(2):188–201.
36. Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Nunez G, Zou W. Interleukin (IL)-10 ablation promotes tumor development, growth metastasis. Cancer Res. 2012;72(2):420–429.
37. Roby KF, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21(4):585–591.
38. Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity. 2004;20(3):327–336.
39. Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol. 1998;10(10):1563–1572.
40. Zou W, et al. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol. 2000;165(8):4388–4396.
41. Cui TX, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39(3):611–621.
42. Wang W, et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell. 2016;165(5):1092–1105.